Compare Matson Inc (MATX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Mesoblast Limited — how do they compare? Matson Inc trades at $204.7 (market cap $6.24B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Matson Inc is far larger — about 2.9× Mesoblast Limited's market cap, and Matson Inc pays a 0.73% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MATX | MESO | |
|---|---|---|
Market Cap | $6.24B | $2.16B |
Sector | Technology | Technology |
52-Week High | $223.55 | $20.96 |
52-Week Low | $88.05 | $12.88 |
Enterprise Value | $6.84B | $2.17B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $206.77, up 0.25% today, with strong technical momentum showing bullish moving averages and support at $205. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $4.27 versus $3.79 expected, and has raised full-year guidance. Valuation remains attractive with a P/E of 14.08 and EV/EBITDA of 7.93, while profitability metrics show a net income margin of 13.41% and ROE of 17.21%.
Outlook remains positive with analyst consensus pointing to 27% upside to $265 price target, supported by continued momentum in China services and resilient consumer demand. Key risks include exposure to Trans-Pacific trade volatility and competitive pressures in shipping markets. The combination of earnings momentum, reasonable valuation, and institutional support suggests favorable risk-reward for investors.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
